GlassScriptPhysician profile
Ravisha Bai
NPI 1598162265
$2,703.21
in general payments reported to CMS, 2019-2025
24 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $326 · 2023: $599 · 2024: $1,498 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $355.88 | 2022-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $244.94 | 2022-2025 | |
| Insulet Corporation | $226.64 | 2024-2025 | Omnipod |
| Abbvie INC. | $202.77 | 2024-2025 | |
| Abbott Laboratories | $197.13 | 2024-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $194.80 | 2023-2025 | Afrezza |
| Lilly USA, LLC | $188.60 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $187.50 | 2023-2024 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $158.37 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.22 | 2023-2024 | Jardiance, Tradjenta, Synjardy |
| Medtronic, INC. | $107.83 | 2023-2025 | Minimed 780g, Minimed 770g |
| Xeris Pharmaceuticals, INC. | $88.84 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $83.74 | 2023-2024 | Lokelma |
| Sanofi-Aventis U.S. LLC | $67.22 | 2023-2024 | |
| Amarin Pharma, INC. | $59.46 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $41.49 | 2022-2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.23 | 2022-2024 | Cycloset |
| Tandem Diabetes Care, INC. | $31.75 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $29.20 | 2024 | |
| Esperion Therapeutics, INC. | $22.94 | 2023 | Nexletol |
| Embecta Corp. | $20.84 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ipsen Biopharmaceuticals, INC | $17.28 | 2022 | |
| Horizon Therapeutics Plc | $14.71 | 2023 | Tepezza |
| Cequr Corporation | $10.83 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravisha Bai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.